Aids

• 

  Publication Venue For

  • A Holistic framework to integrate HIV and cardiovascular disease care in sub-saharan Africa. 2023
  • Longitudinal patterns of initiation, persistence, and cycling on preexposure prophylaxis among female sex workers and adolescent girls and young women in South Africa..  37:977-986. 2023
  • Ideal cardiovascular health, biomarkers, and coronary artery disease in persons with HIV..  37:423-434. 2023
  • Effects of early human immunodeficiency virus infection on cerebral white matter blood flow autoregulation..  37:359-361. 2023
  • HTPN 078: an enhanced case management study to achieve viral suppression among viremic HIV-positive men who have sex with men in the United States..  37:217-231. 2023
  • Diet in a global cohort of adults with HIV at low-to-moderate traditional cardiovascular disease risk..  36:1997-2003. 2022
  • HIV on the brain: is neurosignalling damage irreversible even on antiretroviral therapy?.  35:1503-1504. 2021
  • To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment..  35:1201-1208. 2021
  • Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis..  35:1147-1149. 2021
  • HIV-1 infection of the kidney: mechanisms and implications..  35:359-367. 2021
  • TRIGGERED: could refocused cell signaling be key to natural killer cell-based HIV immunotherapeutics?.  35:165-176. 2021
  • Antiretroviral therapy reduces but does not normalize immune and vascular inflammatory markers in adults with chronic HIV infection in Kenya..  35:45-51. 2021
  • Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection..  34:1923-1931. 2020
  • Exploring patterns and predictors of suicidal ideation among pregnant and postpartum women living with HIV in Kilimanjaro, Tanzania..  34:1657-1664. 2020
  • Proliferation of HIV-infected renal epithelial cells following virus acquisition from infected macrophages..  34:1581-1591. 2020
  • Early cardiac dysfunction in children and young adults with perinatally acquired HIV..  34:539-548. 2020
  • HIV drug resistance in a cohort of HIV-infected MSM in the United States..  34:91-101. 2020
  • Higher soluble CD14 levels are associated with lower visuospatial memory performance in Youth with HIV (YWH). 2019
  • CD8+ T cells: mechanistic target of rapamycin and eukaryotic initiation factor 2 in elite HIV-1 control..  32:2835-2838. 2018
  • Probable antenatal depression at antiretroviral initiation and postpartum viral suppression and engagement in care..  32:2827-2833. 2018
  • Progressive lentivirus infection induces natural killer cell receptor-expressing B cells in the gastrointestinal tract..  32:1571-1578. 2018
  • Building on the HIV chronic care platform to address noncommunicable diseases in sub-Saharan Africa: a research agenda..  32 Suppl 1:S107-S113. 2018
  • Antiretroviral drug concentrations in hair are associated with virologic outcomes among young people living with HIV in Tanzania..  32:1115-1123. 2018
  • Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination..  32:F1-F4. 2018
  • Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals..  32:739-749. 2018
  • Development of broad neutralization activity in simian/human immunodeficiency virus-infected rhesus macaques after long-term infection..  32:555-563. 2018
  • Comparative effectiveness of dual vs. single-action antidepressants on HIV clinical outcomes in HIV-infected people with depression..  31:2515-2524. 2017
  • Relationship between ever reporting depressive symptoms and all-cause mortality in a cohort of HIV-infected adults in routine care..  31:1009-1016. 2017
  • Defining the HIV pre-exposure prophylaxis care continuum..  31:731-734. 2017
  • Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability..  30:2815-2822. 2016
  • HIV infection-induced transcriptional program in renal tubular epithelial cells activates a CXCR2-driven CD4+ T-cell chemotactic response..  30:1877-1888. 2016
  • Frequency of atazanavir-associated leukocyturia development and renal function decline..  30:1488-1489. 2016
  • Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women..  30:1005-1014. 2016
  • CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States..  29:2109-2119. 2015
  • The effect of antidepressant treatment on HIV and depression outcomes: results from a randomized trial..  29:1975-1986. 2015
  • Identification of HIV-1 genitourinary tract compartmentalization by analyzing the env gene sequences in urine..  29:1651-1657. 2015
  • Observations on home HIV testing..  29:1421-1422. 2015
  • The burden of dialysis-requiring acute kidney injury among hospitalized adults with HIV infection: a nationwide inpatient sample analysis..  29:1061-1066. 2015
  • Impact of HIV on lung tumorigenesis in an animal model..  29:633-635. 2015
  • Renal epithelial cells produce and spread HIV-1 via T-cell contact..  28:2345-2353. 2014
  • Ending the invisibility of sex workers in the US HIV/AIDS surveillance and prevention strategy..  28:2325-2327. 2014
  • 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque..  28:2061-2070. 2014
  • Differential expression of the alternatively spliced OPRM1 isoform μ-opioid receptor-1K in HIV-infected individuals..  28:19-30. 2014
  • The increase in global HIV epidemics in MSM..  27:2665-2678. 2013
  • Understanding HIV epidemics: aggregate viral load metrics and 'smoking guns'..  27:2825-2826. 2013
  • Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria..  27:1159-1165. 2013
  • Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings..  26:1345-1354. 2012
  • The design and evaluation of HIV-1 vaccines..  26:1293-1302. 2012
  • Falling through the cracks: the gaps between depression prevalence, diagnosis, treatment, and response in HIV care..  26:656-658. 2012
  • Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques..  26:275-284. 2012
  • High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia..  26:149-155. 2012
  • Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults..  26:45-56. 2012
  • Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection..  25:2089-2097. 2011
  • Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting..  25:1471-1479. 2011
  • IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin..  25:1025-1033. 2011
  • Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection..  25:941-949. 2011
  • Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication..  25:871-872. 2011
  • Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population..  25:513-518. 2011
  • Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline..  25:269-271. 2011
  • Two-year impacts on employment and income among adults receiving antiretroviral therapy in Tamil Nadu, India: a cohort study..  25:239-246. 2011
  • Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T-cell activation following therapy..  24:1281-1290. 2010
  • Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients..  24:F23-F29. 2010
  • HIV-1 viral protein r induces ERK and caspase-8-dependent apoptosis in renal tubular epithelial cells..  24:1107-1119. 2010
  • Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection..  24:875-884. 2010
  • Reply to 'Quantification of HIV-1 RNA on Dried Blood Spots' AIDS 24:475-6..  24:785-786. 2010
  • A polymorphism in the HCP5 gene associated with HLA-B*5701 does not restrict HIV-1 in vitro..  24:155-157. 2010
  • Caveats associated with the use of human cervical tissue for HIV and microbicide research..  24:1-4. 2010
  • Evaluation of a dried blood spot HIV-1 RNA program for early infant diagnosis and viral load monitoring at rural and remote healthcare facilities..  23:2459-2466. 2009
  • HIV-1 Vpr activates the DNA damage response in renal tubule epithelial cells..  23:2054-2056. 2009
  • Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor..  23:1631-1640. 2009
  • Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers..  23:897-906. 2009
  • Interruption of antiretroviral therapy is associated with increased plasma cystatin C..  23:71-82. 2009
  • Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy..  22:2267-2277. 2008
  • The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis..  22:1799-1807. 2008
  • HIV immune reconstitution syndrome in sub-Saharan Africa..  22:1689-1690. 2008
  • Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals..  22:1425-1431. 2008
  • Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells..  22:1131-1135. 2008
  • Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study..  22:601-610. 2008
  • Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope..  22:339-348. 2008
  • Thrombotic thrombocytopenic purpura during immune reconstitution..  21:2559-2560. 2007